Aluffi Valletti Paolo, Brucoli Matteo, Boffano Paolo, Benech Arnaldo, Toso Andrea, Dell'Era Valeria, Garzaro Massimiliano
ENT Division, University Hospital "Maggiore della Carità", University of Eastern Piedmont, Novara, Italy.
Division of Maxillofacial Surgery, University Hospital "Maggiore della Carità", University of Eastern Piedmont, Novara, Italy.
Oral Maxillofac Surg. 2020 Mar;24(1):109-115. doi: 10.1007/s10006-020-00832-z. Epub 2020 Jan 20.
Lymphangiomas are relatively uncommon head and neck region lymphatic malformations. Although surgery can be still considered the mainstay of treatment, sclerotherapy by OK-432 is becoming a widespread treatment option. The aim of this article is to present and discuss the management and outcomes of a series of cases of lymphangiomas.
All patients with lymphangiomas who were treated from 2010 to 2018 were reviewed. The following data were recorded: age, gender, subtype, staging, type of treatment, outcome, and recurrence.
Fifteen patients (9 females, 6 males) were included with 2 microcystic and 13 macrocystic lymphangiomas. Six patients underwent surgery with excision (5 with a complete success, one with a fair success), whereas the remaining 9 subjects underwent sclerotherapy by OK-432 (6 with a complete success, 3 with a fair success). No postoperative complications were observed.
All modes of treatment are important in properly selected patients affected by lymphangiomas. OK-432 therapy is a safe and effective option in the treatment of head and neck lymphangiomas.
淋巴管瘤是相对罕见的头颈部淋巴管畸形。尽管手术仍可被视为主要治疗方法，但使用OK-432进行硬化治疗正成为一种广泛应用的治疗选择。本文旨在介绍并讨论一系列淋巴管瘤病例的治疗及结果。
回顾了2010年至2018年期间接受治疗的所有淋巴管瘤患者。记录了以下数据：年龄、性别、亚型、分期、治疗类型、结果和复发情况。
纳入了15例患者（9例女性，6例男性），其中2例为微囊型淋巴管瘤，13例为大囊型淋巴管瘤。6例患者接受了手术切除（5例完全成功，1例效果尚可），其余9例患者接受了OK-432硬化治疗（6例完全成功，3例效果尚可）。未观察到术后并发症。
对于适当选择的淋巴管瘤患者，所有治疗方式都很重要。OK-432治疗是治疗头颈部淋巴管瘤的一种安全有效的选择。
